A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Tabalumab (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2014 Planned End Date changed from 1 Nov 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 07 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.